Originally published as JCO Early Release 10.1200/JCO.2005.07.093 on November 22 2004

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pietras, K. Articles by Hanahan, D. Search for Related Content PubMed PubMed Citation Articles by Pietras, K. Articles by Hanahan, D.

A Multitargeted, Metronomic, and Maximum-Tolerated Dose "Chemo-Switch" Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of Cancer

Kristian Pietras, Douglas Hanahan

From the Department of Biochemistry and Biophysics, Diabetes and Comprehensive Cancer Centers, University of California San Francisco, San Francisco, CA

Address reprint requests to Douglas Hanahan, MD, University of California San Francisco, 513 Parnassas Avenue, San Francisco, CA 94143; e-mail: dh{at}biochem.ucsf.edu.

PURPOSE: A transgenic mouse model has revealed parameters of the angiogenic switch during multistep tumorigenesis of pancreatic islets, and demonstrated efficacy of antiangiogenic therapies. Pericytes have been revealed as functionally important for tumor neovasculature, using kinase inhibitors targeting their platelet-derived growth factor receptors (PDGFRs). Additionally, vascular endothelial growth factor receptor (VEGFR) inhibitors and metronomic chemotherapy show modest benefit against early- but not late-stage disease.

MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.

RESULTS: Imatinib, despite equivocal efficacy as monotherapy, reduced pericyte coverage of tumor vessels and enhanced efficacy in combination with metronomic chemotherapy or VEGFR inhibition. A regimen involving all three was even better. MTD using cyclophosphamide caused transitory regression, but then rapid regrowth, in contrast to metronomic cyclophosphamide plus imatinib, which produced stable disease. The MTD regimen elicited apoptosis of tumor cells but not endothelial cells, whereas the other regimens increased endothelial cell apoptosis concordant with efficacy. A "chemo-switch" protocol, involving sequential MTD and then metronomic chemotherapy, overlaid with multitargeted inhibition of PDGFR and VEGFR, gave complete responses and unprecedented survival advantage in this model.

CONCLUSION: This study demonstrates a potentially tractable clinical strategy in a stringent preclinical model, wherein standard-of-care chemotherapy is followed by a novel maintenance regimen: PDFGR is targeted to disrupt pericyte support, while metronomic chemotherapy and/or VEGFR inhibitors target consequently sensitized endothelial cells, collectively destabilizing pre-existing tumor vasculature and inhibiting ongoing angiogenesis.

Supported by grants from the National Cancer Institute and the William K. Bowes, Jr Foundation.

K.P. is the recipient of a Swedish Cancer Foundation postdoctoral fellowship.

Terms in blue are defined in the glossary, found at the end of this issue and online at www.jco.org.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				P. C. Maciag, M. M. Seavey, Z.-K. Pan, S. Ferrone, and Y. Paterson Cancer Immunotherapy Targeting the High Molecular Weight Melanoma-Associated Antigen Protein Results in a Broad Antitumor Response and Reduction of Pericytes in the Tumor Vasculature Cancer Res., October 1, 2008; 68(19): 8066 - 8075. [Abstract] [Full Text] [PDF]

				B. Laquente, C. Lacasa, M. M. Ginesta, O. Casanovas, A. Figueras, M. Galan, I. G. Ribas, J. R. Germa, G. Capella, and F. Vinals Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model Mol. Cancer Ther., March 1, 2008; 7(3): 638 - 647. [Abstract] [Full Text] [PDF]

				J. Ma and D. J. Waxman Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib Mol. Cancer Ther., January 1, 2008; 7(1): 79 - 89. [Abstract] [Full Text] [PDF]

				M. Caballero, J. J. Grau, J. L. Blanch, J. Domingo-Domenech, J. M. Auge, W. Jimenez, and M. Bernal-Sprekelsen Serum Vascular Endothelial Growth Factor as a Predictive Factor in Metronomic (Weekly) Paclitaxel Treatment for Advanced Head and Neck Cancer Arch Otolaryngol Head Neck Surg, November 1, 2007; 133(11): 1143 - 1148. [Abstract] [Full Text] [PDF]

				J. Ma and D. J. Waxman Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment Mol. Cancer Ther., November 1, 2007; 6(11): 2879 - 2890. [Abstract] [Full Text] [PDF]

				B. Sennino, B. L. Falcon, D. McCauley, T. Le, T. McCauley, J. C. Kurz, A. Haskell, D. M. Epstein, and D. M. McDonald Sequential Loss of Tumor Vessel Pericytes and Endothelial Cells after Inhibition of Platelet-Derived Growth Factor B by Selective Aptamer AX102 Cancer Res., August 1, 2007; 67(15): 7358 - 7367. [Abstract] [Full Text] [PDF]

				K. M. Bell-McGuinn, A. L. Garfall, M. Bogyo, D. Hanahan, and J. A. Joyce Inhibition of Cysteine Cathepsin Protease Activity Enhances Chemotherapy Regimens by Decreasing Tumor Growth and Invasiveness in a Mouse Model of Multistage Cancer Cancer Res., August 1, 2007; 67(15): 7378 - 7385. [Abstract] [Full Text] [PDF]

				I Duran, R Salazar, O Casanovas, V Arrazubi, E Vilar, L. Siu, J Yao, and J Tabernero New drug development in digestive neuroendocrine tumors Ann. Onc., August 1, 2007; 18(8): 1307 - 1313. [Abstract] [Full Text] [PDF]

				J. E. Bauman, K. D. Eaton, and R. G. Martins Antagonism of Platelet-Derived Growth Factor Receptor in Non Small Cell Lung Cancer: Rationale and Investigations Clin. Cancer Res., August 1, 2007; 13(15): 4632s - 4636s. [Abstract] [Full Text] [PDF]

				M. E. Kutcher, A. Y. Kolyada, H. K. Surks, and I. M. Herman Pericyte Rho GTPase Mediates Both Pericyte Contractile Phenotype and Capillary Endothelial Growth State Am. J. Pathol., August 1, 2007; 171(2): 693 - 701. [Abstract] [Full Text] [PDF]

				U. Emmenegger, Y. Shaked, S. Man, G. Bocci, I. Spasojevic, G. Francia, A. Kouri, R. Coke, W. Cruz-Munoz, S. M. Ludeman, et al. Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice Mol. Cancer Ther., August 1, 2007; 6(8): 2280 - 2289. [Abstract] [Full Text] [PDF]

				H. M.W. Verheul, H. Hammers, K. van Erp, Y. Wei, T. Sanni, B. Salumbides, D. Z. Qian, G. D. Yancopoulos, and R. Pili Vascular Endothelial Growth Factor Trap Blocks Tumor Growth, Metastasis Formation, and Vascular Leakage in an Orthotopic Murine Renal Cell Cancer Model Clin. Cancer Res., July 15, 2007; 13(14): 4201 - 4208. [Abstract] [Full Text] [PDF]

				C. Lu, A. A. Kamat, Y. G. Lin, W. M. Merritt, C. N. Landen, T. J. Kim, W. Spannuth, T. Arumugam, L. Y. Han, N. B. Jennings, et al. Dual Targeting of Endothelial Cells and Pericytes in Antivascular Therapy for Ovarian Carcinoma Clin. Cancer Res., July 15, 2007; 13(14): 4209 - 4217. [Abstract] [Full Text] [PDF]

				A. Wicki, D. Wild, D. Storch, C. Seemayer, M. Gotthardt, M. Behe, S. Kneifel, M. J. Mihatsch, J.-C. Reubi, H. R. Macke, et al. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 Is a Highly Efficient Radiotherapeutic for Glucagon-Like Peptide-1 Receptor-Targeted Therapy for Insulinoma Clin. Cancer Res., June 15, 2007; 13(12): 3696 - 3705. [Abstract] [Full Text] [PDF]

				L. Q.M. Chow and S. G. Eckhardt Sunitinib: From Rational Design to Clinical Efficacy J. Clin. Oncol., March 1, 2007; 25(7): 884 - 896. [Abstract] [Full Text] [PDF]

				C. Gridelli, P. Maione, F. Del Gaizo, G. Colantuoni, C. Guerriero, C. Ferrara, D. Nicolella, D. Comunale, A. De Vita, and A. Rossi Sorafenib and Sunitinib in the Treatment of Advanced Non-Small Cell Lung Cancer Oncologist, February 1, 2007; 12(2): 191 - 200. [Abstract] [Full Text] [PDF]

				J. Baranowska-Kortylewicz, M. Abe, J. Nearman, and C. A. Enke Emerging Role of Platelet-Derived Growth Factor Receptor-{beta} Inhibition in Radioimmunotherapy of Experimental Pancreatic Cancer Clin. Cancer Res., January 1, 2007; 13(1): 299 - 306. [Abstract] [Full Text] [PDF]

				Y. Kitadai, T. Sasaki, T. Kuwai, T. Nakamura, C. D. Bucana, and I. J. Fidler Targeting the Expression of Platelet-Derived Growth Factor Receptor by Reactive Stroma Inhibits Growth and Metastasis of Human Colon Carcinoma Am. J. Pathol., December 1, 2006; 169(6): 2054 - 2065. [Abstract] [Full Text] [PDF]

				F. Pastorino, C. Brignole, D. Di Paolo, B. Nico, A. Pezzolo, D. Marimpietri, G. Pagnan, F. Piccardi, M. Cilli, R. Longhi, et al. Targeting Liposomal Chemotherapy via Both Tumor Cell-Specific and Tumor Vasculature-Specific Ligands Potentiates Therapeutic Efficacy. Cancer Res., October 15, 2006; 66(20): 10073 - 10082. [Abstract] [Full Text] [PDF]

				C. Lamagna and G. Bergers The bone marrow constitutes a reservoir of pericyte progenitors J. Leukoc. Biol., October 1, 2006; 80(4): 677 - 681. [Abstract] [Full Text] [PDF]

				M. F. McCarty and K. I. Block Preadministration of High-Dose Salicylates, Suppressors of NF-{kappa}B Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation Therapy. Integr Cancer Ther, September 1, 2006; 5(3): 252 - 268. [Abstract] [PDF]

				S. S.W. Ng, A. Sparreboom, Y. Shaked, C. Lee, S. Man, N. Desai, P. Soon-Shiong, W. D. Figg, and R. S. Kerbel Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL-Based Paclitaxel. Clin. Cancer Res., July 15, 2006; 12(14): 4331 - 4338. [Abstract] [Full Text] [PDF]

				M. F. McCarty and K. I. Block Toward a core nutraceutical program for cancer management. Integr Cancer Ther, June 1, 2006; 5(2): 150 - 171. [Abstract] [PDF]

				R. S. Kerbel Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science, May 26, 2006; 312(5777): 1171 - 1175. [Abstract] [Full Text] [PDF]

				R. Munoz, S. Man, Y. Shaked, C. R. Lee, J. Wong, G. Francia, and R. S. Kerbel Highly Efficacious Nontoxic Preclinical Treatment for Advanced Metastatic Breast Cancer Using Combination Oral UFT-Cyclophosphamide Metronomic Chemotherapy. Cancer Res., April 1, 2006; 66(7): 3386 - 3391. [Abstract] [Full Text] [PDF]

				E. Naumova, P. Ubezio, A. Garofalo, P. Borsotti, L. Cassis, E. Riccardi, E. Scanziani, S. A. Eccles, M. R. Bani, and R. Giavazzi The Vascular Targeting Property of Paclitaxel Is Enhanced by SU6668, a Receptor Tyrosine Kinase Inhibitor, Causing Apoptosis of Endothelial Cells and Inhibition of Angiogenesis. Clin. Cancer Res., March 15, 2006; 12(6): 1839 - 1849. [Abstract] [Full Text] [PDF]

				V. J. Yao, M. G. Ozawa, A. S. Varner, I. M. Kasman, Y. H. Chanthery, R. Pasqualini, W. Arap, and D. M. McDonald Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels. Cancer Res., March 1, 2006; 66(5): 2639 - 2649. [Abstract] [Full Text] [PDF]

				U. Emmenegger, G. C. Morton, G. Francia, Y. Shaked, M. Franco, A. Weinerman, S. Man, and R. S. Kerbel Low-Dose Metronomic Daily Cyclophosphamide and Weekly Tirapazamine: A Well-Tolerated Combination Regimen with Enhanced Efficacy That Exploits Tumor Hypoxia Cancer Res., February 1, 2006; 66(3): 1664 - 1674. [Abstract] [Full Text] [PDF]

				J. M. du Manoir, G. Francia, S. Man, M. Mossoba, J. A. Medin, A. Viloria-Petit, D. J. Hicklin, U. Emmenegger, and R. S. Kerbel Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts Clin. Cancer Res., February 1, 2006; 12(3): 904 - 916. [Abstract] [Full Text] [PDF]

				K. Yokoi, T. Sasaki, C. D. Bucana, D. Fan, C. H. Baker, Y. Kitadai, T. Kuwai, J. L. Abbruzzese, and I. J. Fidler Simultaneous Inhibition of EGFR, VEGFR, and Platelet-Derived Growth Factor Receptor Signaling Combined with Gemcitabine Produces Therapy of Human Pancreatic Carcinoma and Prolongs Survival in an Orthotopic Nude Mouse Model Cancer Res., November 15, 2005; 65(22): 10371 - 10380. [Abstract] [Full Text] [PDF]

				E. Hendershot Treatment Approaches for Metastatic Ewing's Sarcoma: A Review of the Literature Journal of Pediatric Oncology Nursing, November 1, 2005; 22(6): 339 - 352. [Abstract] [PDF]

				Y. Shaked, U. Emmenegger, S. Man, D. Cervi, F. Bertolini, Y. Ben-David, and R. S. Kerbel Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity Blood, November 1, 2005; 106(9): 3058 - 3061. [Abstract] [Full Text] [PDF]

				G. Bergers and S. Song The role of pericytes in blood-vessel formation and maintenance Neuro-oncol, October 1, 2005; 7(4): 452 - 464. [Abstract] [PDF]

				R. Yap, D. Veliceasa, U. Emmenegger, R. S. Kerbel, L. M. McKay, J. Henkin, and O. V. Volpert Metronomic Low-Dose Chemotherapy Boosts CD95-Dependent Antiangiogenic Effect of the Thrombospondin Peptide ABT-510: A Complementation Antiangiogenic Strategy Clin. Cancer Res., September 15, 2005; 11(18): 6678 - 6685. [Abstract] [Full Text] [PDF]

				R. Demicheli, R. Miceli, A. Moliterni, M. Zambetti, W. J. M. Hrushesky, M. W. Retsky, P. Valagussa, and G. Bonadonna Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process Ann. Onc., September 1, 2005; 16(9): 1449 - 1457. [Abstract] [Full Text] [PDF]

				G. Bocci, M. Tuccori, U. Emmenegger, V. Liguori, A. Falcone, R. S. Kerbel, and M. Del Tacca Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation Ann. Onc., August 1, 2005; 16(8): 1243 - 1252. [Abstract] [Full Text] [PDF]